Literature DB >> 17378373

Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms.

Hideo Ikeda1, Teruo Inoue, Shumpo Uemura, Ryota Kaibara, Hiroyuki Tanaka, Koichi Node.   

Abstract

Hypertension in middle-aged or elderly women is often accompanied with various symptoms, which may be related to climacteric. The symptoms of post-menopausal women are suggested to be derived in part from instability of the sympathetic nerve system due to a low estrogen state. An angiotensin-receptor blocker, candesartan cilexetil (candesartan), is known to suppress sympathetic nerve activity by inhibiting the renin-angiotensin system in the brain, suggesting that it may be effective for ameliorating these symptoms. The aim of this study was to elucidate whether candesartan improves menopausal symptoms in hypertensive women. A total of 69 female patients, aged 40 years or older, who had hypertension and various menopausal-like symptoms, were recruited from 39 centers to participate in this study. Patients were prescribed candesartan 4 to 8 mg/day (average dose 7.2 mg/day), alone or in addition to current antihypertensive medications. We interviewed patients in regard to their menopausal symptoms and scored them using the Simplified Menopausal Index (SMI). During the 12-month observation period, significant decreases were seen in both blood pressure (157+/-21/85+/-11 to 141+/-18/77+/-12 mmHg, p<0.001) and SMI (29+/-18 to 18+/-7, p<0.001), although the heart rate did not change. The percentage of decrease in SMI was correlated with that in systolic blood pressure (r=0.43, p<0.001). Candesartan may be an effective antihypertensive agent to relieve menopausal-like symptoms in middle-aged or elderly hypertensive women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17378373     DOI: 10.1291/hypres.29.1007

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  4 in total

1.  Gender differences in coronary heart disease.

Authors:  A H E M Maas; Y E A Appelman
Journal:  Neth Heart J       Date:  2010-12       Impact factor: 2.380

2.  Women's health in menopause with a focus on hypertension.

Authors:  A H E M Maas; H R Franke
Journal:  Neth Heart J       Date:  2009-02       Impact factor: 2.380

3.  17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex.

Authors:  David E Harrison; Randy Strong; Peter Reifsnyder; Navasuja Kumar; Elizabeth Fernandez; Kevin Flurkey; Martin A Javors; Marisa Lopez-Cruzan; Francesca Macchiarini; James F Nelson; Adrian Markewych; Alessandro Bitto; Amy L Sindler; Gino Cortopassi; Kylie Kavanagh; Lin Leng; Richard Bucala; Nadia Rosenthal; Adam Salmon; Timothy M Stearns; Molly Bogue; Richard A Miller
Journal:  Aging Cell       Date:  2021-03-31       Impact factor: 11.005

4.  Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.

Authors:  Xudong Zhao; Xietong Wang
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.